Welcome to our dedicated page for Cv Sciences SEC filings (Ticker: CVSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CV Sciences, Inc. (OTCQB:CVSI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports and other documents that explain its financial condition, capital structure, and material agreements. CV Sciences presents itself as a consumer wellness company focused on hemp extracts, nutraceuticals, and plant-based foods, and its filings offer detail on how this strategy is reflected in its operations and financing.
Recent Form 8-K filings describe material events such as note purchase agreements and secured promissory notes with institutional investors. These reports outline original issuance discounts, net proceeds, maturity dates, repayment schedules, and security interests in the assets of CV Sciences and its subsidiaries. They also summarize customary events of default, potential increases to outstanding balances upon default, and the circumstances under which amounts can be declared immediately due and payable.
Other 8-K filings incorporate by reference the company’s earnings press releases, which include GAAP financial statements and non-GAAP measures like Adjusted EBITDA. In these disclosures, CV Sciences explains why management uses non-GAAP metrics, how they reconcile to GAAP results, and how they are intended to highlight trends in the business.
Through Stock Titan, users can review these filings alongside AI-powered summaries that clarify key terms in note purchase agreements, security agreements, and intellectual property security agreements. The platform also helps surface important items in quarterly and annual reports, such as product sales, gross margin, operating income or loss, and cash flow trends, without requiring readers to parse every line of the underlying documents.
Investors interested in CVSI can use this page to monitor new 8-Ks and other SEC submissions as they are posted to EDGAR, while AI-generated insights provide plain-language explanations of complex financing structures and reporting conventions.
CV Sciences, Inc. entered into an agreement with its institutional investor to amend and restate two secured promissory notes into senior secured convertible notes. The Amended Notes now carry a fixed conversion price of
The notes’ outstanding principal was increased by 20%, giving an aggregate principal of
A true-up feature aims to ensure the investor’s net sale proceeds equal the principal converted; if the aggregate shortfall across both notes exceeds
CV Sciences, Inc. reported Q3 results marked by softer sales and tight liquidity while taking steps to refinance debt and reduce obligations. Product sales, net were
Cash was
Management disclosed substantial doubt about continuing as a going concern and noted new federal legislation effective
CV Sciences, Inc. furnished an 8‑K announcing it issued a press release covering financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference into Item 2.02 via Item 7.01.
The release includes non‑GAAP financial measures with GAAP reconciliations and related explanations. The information is furnished, not filed, and includes forward‑looking statements that are subject to risks and uncertainties.
CV Sciences, Inc. entered into a new note purchase agreement with an institutional investor and issued a secured promissory note with an original principal amount of $600,000. After a $150,000 original issuance discount, a $150,000 payment tied to modifying a prior purchase agreement, and $13,125 of legal and other fees, the Company received net proceeds of $300,000.
The Note is secured by all of the Company’s assets and the assets and intellectual property of its subsidiaries under a Security Agreement and an Intellectual Property Security Agreement dated October 6, 2025. Monthly repayments of $46,153.85 begin on April 6, 2026, with all unpaid amounts due by April 6, 2027, and an 8% discount applies if the Note is fully repaid within six months of closing.
The Note includes customary events of default. On certain events of default, the investor may increase the outstanding balance by 20% or 5%, declare all amounts immediately due, and begin charging interest on the outstanding balance at up to 18% per annum or the maximum rate allowed by law.
CV Sciences, Inc. entered into an agreement with an institutional investor to amend its existing secured promissory note originally issued for a principal amount of
The amendment extends the note’s maturity to